PREFACE HISTORY METHODS APPLICATIONS PRODUCTS RESOURCES CONTACT
Select a Product
CLOSE

Select Your Mirus Solution

Find products by cell type with Reagent Agent
TOP
PLAY
 
Calcium Phosphate
Introduction of chemical transfection
Drs. F.L. Graham and A. J. van der Eb first use calcium phosphate as a nonviral means to deliver nucleic acids.

Graham et al. Virology. 52(2):456-67.
Viral Vectors
Recombinant viral vectors for expression
Viral vectors (SV40) used to infect mammalian cells to produce functional mRNA and protein.

Mulligan et al. Nature. 277(5692):108-14.
Hamer et al. Cell. 17(3):725-35.
Electroporation
Electroporation first introduced
Dr. Eberhard Neumann introduces electroporation − electrical currents as a means to facilitate DNA uptake.

Neumann et al. EMBO. 1(7):841-845.
Liposome
Liposome based transfection
Felgner et al. first demonstrate cationic liposome mediated transfection.

Felgner et al. PNAS. 84(21):7413-7.
Defining Genes And Implications On Gene Transfer
Defining Genes and
Implications on Gene Transfer
In vivo DNA Delivery
Jon Wolff and colleagues at the University of Wisconsin are the first to show that naked plasmid DNA could be taken up and expressed by muscle cells in vivo.

Wolff et al. Science. 247:1465–1468, 1990.
Importance Of Low Toxicity Gene Transfer
Importance of Low Toxicity Gene Delivery
First Mirus Bio product launch - DNA transfection
TransIT®-LT1 Transfection Reagent – Development of the first serum-compatible transfection reagent.

In vivo DNA delivery
First demonstration that plasmid DNA could be delivered effectively into liver cells in vivo (mice) using rapid intravascular injections.

Budker et al. Gene Therapy. 3:593–598, 1996.
Nucleic Acid Labeling
Mirus Bio for nucleic acid labeling
Development of Label IT® Technology to complement transfection. Label IT® allows direct chemical fluorescent and non-fluorescent labeling that is nondestructive, stable, and preserves nucleic acid function, making the technology ideal for use in tracking.
Initial Hurdles For Gene Transfer
Initial Hurdles for Gene Transfer
In vivo DNA delivery
First demonstration that plasmid DNA could be delivered effectively into skeletal muscle cells in vivo using rapid intravascular injections

Budker et al. Gene Therapy. 5:272–276, 1998.
In Vivo DNA Delivery
In vivo DNA delivery
First demonstration of high efficiency gene delivery to mouse liver following a rapid injection of plasmid DNA into the tail vein.

Zhang et al. Human Gene Therapy. 10:1735–1737, 1999.

First demonstration that “caged” DNA-containing nanoparticles are resistant to aggregation under physiologic salt conditions.

Trubetskoy et al. Bioconjugate Chemistry. 10:624–628, 1999.
TransIT-TKO
Mirus Bio for siRNA transfection
TransIT-TKO® Transfection Reagent – Development and commercialization of the first high efficiency transfection reagent designed specifically for siRNA delivery into cultured mammalian cells.
In vivo siRNA delivery
In vivo siRNA delivery
First demonstration of siRNA-mediated knockdown of an endogenously expressed gene in mice.

Lewis et al. Nature Genetics. 32:107–108, 2002.
DNA-containing nanoparticles
In vivo DNA delivery
Development of low toxicity, DNA-containing nanoparticles for gene delivery to lungs.

Trubetskoy et al. Gene Therapy. 10:261–271, 2003.
TransIT-mRNA
Mirus Bio for mRNA transfection
Development of a high efficiency, low toxicity, large RNA transfection reagent, TransIT®-mRNA Transfection Reagent, for mammalian cells.

In vivo DNA delivery
Development of a nonviral method for delivering genes and siRNAs into mammalian skeletal muscle.

Hagstrom et al. Molecular Therapy. 10:386–398, 2004.
miRNA Labeling
Mirus Bio for miRNA labeling
Development and commercialization of a one- step, nonenzymatic labeling method for microRNA, the Label IT® miRNA Labeling Kit.
RNAi
Nobel Prize for RNAi
Andrew Fire and Craig Mello awarded Nobel Prize in Physiology/Medicine for discovery of RNA interference (RNAi).

In vivo gene delivery
Development of a genetic immunization method in research animals by intravenous delivery.

Bates et al. Biotechniques. 40:199–208, 2006.
Ingenio
Mirus Bio for electroporation
Introduction of Ingenio® Electroporation Kits & Solution to facilitate high efficiency delivery in hard-to-transfect cells on most of the commonly used electroporation devices.

Mirus acquisition
Hoffman-La Roche acquires therapeutic division of Mirus Bio Corporation.
TransIT-2020
Mirus Bio for DNA delivery
Introduction of TransIT®-2020 – High performance broad spectrum DNA delivery that is effective in many cell types and is animal origin-free.
TransIT-PRO
Mirus Bio for protein production
Introduction of TransIT-PRO® Transfection Kit – Ideal for high yield biotherapeutic protein production in suspension CHO and HEK 293 cells.
TransIT-3D
Mirus Bio for 3D transfection
Mirus collaborates with Reinnervate to demonstrate transfection of cells grown in alvetex® 3D scaffolds to introduce the 3D Transfection System with TransIT®-3D Transfection Reagent, which enables biologically relevant transfection.
Custom Services
Mirus Bio custom services
Mirus launches new custom services division for full transfection offering, custom reagent development, and nucleic acid labeling.
TransIT-X2
Breast Cancer Research Mirus Bio for breast cancer research
Introduction of the first breast cancer cell line-specific reagent – TransIT®-BrCa Transfection Reagent.

Mirus Bio for Insect Cells
Introduction of animal origin-free formulation for exceptional DNA delivery and high titer baculovirus production in insect cells – TransIT®-Insect Transfection Reagent.

Mirus Bio transfection breakthrough
Availability of TransIT®-X2 Transfection Reagent – Breakthrough in lipid and polymer chemistry unleashes the best available reagent for DNA delivery with siRNA transfection capabilities.
 

Our Story

Gene delivery is our focus and our passion. Among the founding scientists at Mirus Bio, Vladimir Budker, Jon Wolff and Jim Hagstrom have spent most of their careers studying gene delivery and were instrumental in numerous landmark discoveries relating to in vitro and in vivo nucleic acid delivery and cell culture applications. In 1990, Jon Wolff and colleagues at the University of Wisconsin were the first to show that naked plasmid DNA could be taken up and expressed by muscle cells in vivo . In 1996, Budker and Wolff were the first to demonstrate that naked plasmid DNA could be delivered with high efficiency to liver cells in vivo using a rapid, high volume injection. In 2004, Hagstrom, Hegge, et al., developed a breakthrough method for delivering genes into skeletal muscle using retrograde delivery into veins.

Understanding and perfecting gene delivery to cells in culture has been our goal since before the beginning of Mirus. In 1996, Mirus scientists introduced TransIT® LT-1, a breakthrough transfection reagent that was the first to combine high efficiency delivery with low toxicity (LT-1) to cells. This reagent remains a transfection reagent of choice for many researchers to this day.

 

Subsequent to this ground-breaking research, Mirus Bio developed an impressive portfolio of TransIT® Transfection Reagents and the Ingenio® Electroporation product lines for the delivery of all nucleic acids into a broad variety of cell types. These technologies are backed by nearly 20 years of nucleic acid delivery expertise as outlined in the timeline. Products developed by Mirus Bio are shown in red font.

Company Founders
Mirus Bio founders pictured from left to right: Vladimir Budker, Jon Wolff, and James Hagstrom